Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Acumen Pharmaceuticals, Inc. (ABOS) AI Forecast

Our AI detected a significant signal for Acumen Pharmaceuticals, Inc.. Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$ABOS Bullish Signal Full forecast available
Sign Up Free

Acumen Pharmaceuticals, Inc. (ABOS) Stock Forecast Sept. 5, 2026

Acumen Pharmaceuticals, Inc. (ABOS) AI Stock Price Forecast & Investment Analysis

Acumen Pharmaceuticals, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Acumen Pharmaceuticals, Inc. (ABOS) - Comprehensive Stock Analysis & Investment Research

Deep dive into Acumen Pharmaceuticals, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 5, 2026, 2:18 p.m. (UTC)

Acumen Pharmaceuticals, Inc. Investment Summary

When evaluating whether Acumen Pharmaceuticals, Inc. (ABOS) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Acumen Pharmaceuticals, Inc. (ABOS) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $230 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Acumen Pharmaceuticals, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Acumen Pharmaceuticals, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Acumen Pharmaceuticals, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Acumen Pharmaceuticals, Inc.

Sign Up Free
Corporate Identity

Acumen Pharmaceuticals, Inc. (Stock Symbol: ABOS) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Acumen Pharmaceuticals, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Acumen Pharmaceuticals, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Acumen Pharmaceuticals, Inc....

Unlock Full Company Profile

Get complete details about Acumen Pharmaceuticals, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Acumen Pharmaceuticals, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Acumen Pharmaceuticals, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Acumen Pharmaceuticals, Inc....

Unlock Financial Analysis

Get complete financial metrics for Acumen Pharmaceuticals, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Acumen Pharmaceuticals, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Acumen Pharmaceuticals, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Acumen Pharmaceuticals, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-92 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Acumen Pharmaceuticals, Inc. (ABOS) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Acumen Pharmaceuticals, Inc. stock analysis.

Deep dive into Acumen Pharmaceuticals, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Acumen Pharmaceuticals, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Acumen Pharmaceuticals, Inc.:

P/B Ratio 4.02x
Market Cap $230M
Book Value/Share $0.79
FCF/Share $-1.27
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Acumen Pharmaceuticals, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Acumen Pharmaceuticals, Inc.: An ROE of -617.2% indicates room for improvement in shareholder value creation.

ROE -617.2%
ROA -304.7%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Acumen Pharmaceuticals, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Acumen Pharmaceuticals, Inc.:

D/E Ratio 1.03x
Financial Leverage 2.03x
Interest Coverage -29.3x
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Acumen Pharmaceuticals, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Acumen Pharmaceuticals, Inc.: Free cash flow of $-92M indicates cash challenges that need attention.

Operating Cash Flow -$27M
Free Cash Flow -$92M
Capital Spending -$65M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Acumen Pharmaceuticals, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Acumen Pharmaceuticals, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Acumen Pharmaceuticals, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Acumen Pharmaceuticals, Inc.:

Income Statement
Operating Income -$28M
Net Income -$353M
R&D Expense $19M
Balance Sheet Highlights (% Of Assets)
Total Liabilities 59%
Dividend & Shareholder Information
Shares Outstanding 72M

Latest Acumen Pharmaceuticals, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Acumen Pharmaceuticals, Inc. (ABOS) stock price and investment outlook.

📰 Loading...

Where ABOS sits on the market map

Explore the map →

Acumen Pharmaceuticals, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Acumen Pharmaceuticals, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $230M x 4.0x
ABPO ██% $1M x x
ACOG ██% $207M x 3.9x
ADAPY ██% $8M x x
ADMA ██% $2.17B 12.8x 5.3x
ADPT ██% $3.86B x 27.0x
AGEN ██% $351M 3.8x x
AGTX ██% $800K x x
AIM ██% $7M x 0.9x
ALEC ██% $252M x x
ALGS ██% $39M x 1.2x
ALLO ██% $680M x 1.6x
ALVO ██% $1.90B x x
AMGN ██% $236.37B 27.0x 20.2x
APGE ██% $10.18B x x
APTN ██% $57M x x
APTOF ██% $4M x x
ARGX ██% $65.31B x x
ARMP ██% $217M x x
ARTV ██% $543M x 1.6x
ATRA ██% $92M x x
ATYR ██% $49M x 1.0x
AURA ██% $784M x 2.5x
AUTL ██% $596M x 8.0x
AVXL ██% $266M x 2.1x
BCAB ██% $2M x x
BCDA ██% $16M x 6.0x
BCLI ██% $12M x x
BCRX ██% $2.54B x x
BDTX ██% $122M x 1.3x
BEAM ██% $3.06B x 2.9x
BIIB ██% $32.98B 24.0x 1.8x
BKHA ██% $50M 97.5x x
BNTX ██% $26.06B x x
CABA ██% $588M x 2.8x
CADL ██% $973M x 7.7x
CCCC ██% $462M x 1.9x
CELZ ██% $7M x 0.8x
CERO ██% $790K x x
CGEM ██% $1.42B x 4.4x
CGEN ██% $245M 3.5x 2.4x
CGON ██% $6.59B x 6.4x
CGTX ██% $98M x 3.0x
CHRS ██% $219M x 3.6x
CLDI ██% $3M x 1.1x
CLLS ██% $334M x x
CMPX ██% $427M x 2.6x
COAG ██% $2.07B x 4.6x
CPMV ██% $440K x x
CRDF ██% $84M x 3.2x
CRDL ██% $252M x x
CRIS ██% $3M x 0.7x
CRSP ██% $5.46B x 3.1x
CSBR ██% $73M x 18.6x
CVM ██% $28M x 2.6x
DBVT ██% $861M x 5.4x
DNA ██% $434M x 1.0x
DNLI ██% $3.64B x 4.4x
DTIL ██% $194M x 4.3x
DYAI ██% $20M x x
EDIT ██% $470M x 4.5x
EIKN ██% $588M x 1.3x
ELUT ██% $36M 0.7x 2.3x
ENGN ██% $123M x 0.5x
ENTX ██% $519M x 71.5x
ENZN ██% $67M x 0.4x
ESLA ██% $31M x x
EVAX ██% $28M x x
EXEL ██% $14.69B 17.1x 8.0x
EXOZ ██% $64M x 17.4x
FATE ██% $289M x 1.9x
FDMT ██% $827M x 2.0x
FENC ██% $434M x 10.2x
GILD ██% $185.67B x 15.7x
GLUE ██% $1.18B x 2.4x
GNTA ██% $48M x 3.9x
GPLB ██% $180K x x
GRML ██% $15M x 0.3x
HALO ██% $12.57B 30.4x 87.5x
HUMA ██% $166M x 5.3x
IBRX ██% $8.51B x x
IKT ██% $330M x 2.2x
IMA ██% $55M x 0.4x
IMCR ██% $1.92B x 4.6x
IMTX ██% $1.46B x x
IMVT ██% $8.10B x 11.0x
INAB ██% $12M x 0.6x
INKT ██% $58M x x
INMB ██% $67M x 3.3x
INTS ██% $12M x 1.4x
IOVA ██% $3.98B x 5.4x
IPSC ██% $381M x 1.6x
IVVD ██% $237M x 1.3x
JATT ██% $95M x 0.5x
JSPR ██% $24M x 16.7x
KLRS ██% $93M x 1.6x
KOD ██% $2.22B x 36.4x
KRYS ██% $10.60B 43.9x 7.8x
KYMR ██% $9.82B x 6.5x
KYTX ██% $508M x 3.1x
LCTX ██% $273M x 4.5x
LENZ ██% $187M x 0.9x
LIFE ██% $3.91B x 80.1x
LIMN ██% $5M x 16.6x
LONA ██% $71M x 2.1x
LXEO ██% $384M x 1.6x
MAZE ██% $1.48B x 3.3x
MESO ██% $2.25B x x
MGTX ██% $1.31B 16.6x 6.1x
MGX ██% $44M x 0.4x
MOLN ██% $176M x x
MRNA ██% $58.07B x 8.6x
NBIX ██% $15.81B 22.4x 4.3x
NMRA ██% $256M x 5.7x
NVAX ██% $1.68B x x
OCGN ██% $448M x x
OTLK ██% $162M x x
PALI ██% $363M x 3.0x
PASG ██% $15M x 3.4x
PCVX ██% $8.86B x 3.2x
PHGE ██% $4M x 0.4x
PLUR ██% $18M x x
PLX ██% $214M 11.3x 3.0x
PMCB ██% $5M x 0.2x
PRME ██% $649M x 16.3x
PROK ██% $802M x x
PTHS ██% $91M x x
QGEN ██% $9.39B x 2.5x
QNCX ██% $32M x x
REPL ██% $1.42B x 13.4x
RGEN ██% $9.46B 227.7x 4.5x
RGNX ██% $590M x 8.2x
RLAY ██% $4.05B x 4.5x
RVMD ██% $45.00B x 17.3x
RXRX ██% $1.94B x 2.1x
SABS ██% $313M x 1.5x
SANA ██% $1.15B x 7.5x
SCLX ██% $38M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $62M x x
SLDB ██% $1.08B x 2.9x
SLXN ██% $2M x 46.8x
SNTI ██% $10M x x
SRRK ██% $6.73B x 26.5x
SRZN ██% $268M x x
STRO ██% $333M x x
TARA ██% $225M x 1.4x
TARS ██% $3.93B x 11.3x
TCRX ██% $48M x 0.7x
TECH ██% $11.31B 62.2x 5.4x
TECX ██% $591M x 2.6x
TIL ██% $52M x 0.5x
TNYA ██% $155M x 2.2x
TSHA ██% $1.79B x 4.6x
TVGN ██% $47M x x
TWST ██% $7.85B x 17.6x
VACH ██% $541M 80.4x x
VALN ██% $621M x x
VCEL ██% $2.07B 85.4x 5.6x
VIR ██% $1.92B x 2.0x
VISK ██% $69M x 0.4x
VIVS ██% $4M x x
VOR ██% $1.28B 2.0x x
VXRT ██% $121M 3.2x 1.5x
VYGR ██% $211M x 1.4x
WINT ██% $10K x x
XFOR ██% $388M x 2.5x
ZEOX ██% $9M x 13.1x
ZIVO ██% $14M x x
ZURA ██% $582M x 3.0x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Acumen Pharmaceuticals, Inc. Stock Forecast

How accurate are Acumen Pharmaceuticals, Inc. stock predictions?

Our AI model shows a 3% Spearman correlation coefficient for ABOS predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Acumen Pharmaceuticals, Inc. stock price forecasts?

Our analysis considers Acumen Pharmaceuticals, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Acumen Pharmaceuticals, Inc. a good investment in 2026?

Based on our AI analysis, Acumen Pharmaceuticals, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Acumen Pharmaceuticals, Inc. forecasts updated?

Acumen Pharmaceuticals, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Acumen Pharmaceuticals, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...